Aurobindo Pharma confident of all-round growth in the US market

Aurobindo had reported Rs 19,563.6 crore in revenues in FY19 with an year-on-year growth of 18.5 per cent

Drug major Aurobindo Pharma is confident of growth in the key US market despite recent hiccups on the regulatory front. The company said that it expected all-round growth in the US market with a significant expansion in the company's injectables portfolio going forward.

Aurobindo Pharma's managing director N Govindrajan said that the optimism was based on the fact that 2018-19 had been a busy year for the company's US team.

Although Govindarajan's letter did not mention USFDA's warning letter dated June 20, 2019, which raised serious cGMP lapses in three of Aurobindo's API and formulation facilities, it stated that the company has